Get the Stockscreener App
2.43
0.41%
0.01
After Hours:
2.41
-0.02
-0.82%
Caribou Biosciences Inc stock is traded at $2.43, with a volume of 68.17M.
It is up +0.41% in the last 24 hours and up +7.05% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$2.42
Open:
$3.4
24h Volume:
68.17M
Relative Volume:
33.69
Market Cap:
$226.29M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.6644
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-0.82%
1M Performance:
+7.05%
6M Performance:
+176.14%
1Y Performance:
+9.95%
1-Day Range:
$2.38
$3.535
1-Week Range:
$2.275
$3.535
52-Week Range:
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.43 | 225.36M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Caribou Biosciences Stock Rises 3% After Dual Positive Phase 1 Trial Updates - Nasdaq
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
Caribou Bio leaps on early data for vispa-cel - The Pharma Letter
CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien - GuruFocus
Alert inadvertently tagged to Caribou Biosciences withdrawn - MarketScreener
Comparing Caribou Biosciences Inc. in custom built stock radarsWall Street Watch & Verified Momentum Stock Ideas - newser.com
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - MSN
Ranking Caribou Biosciences Inc. among high performing stocks via toolsPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Is it time to cut losses on Caribou Biosciences Inc.Weekly Investment Recap & Smart Swing Trading Alerts - newser.com
Will Caribou Biosciences Inc. stock go up soonMarket Activity Report & Fast Moving Trade Plans - newser.com
Caribou Biosciences expects cash and marketable securities as of Sept 30 to be $159.2 million - MarketScreener
Caribou Biosciences Reports Positive ANTLER Phase 1 Results - TipRanks
Using flow based indicators on Caribou Biosciences Inc.July 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Caribou Biosciences announces results from CaMMouflage Phase 1 trial - TipRanks
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - The Manila Times
Caribou Biosciences stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com Canada
Why Caribou Biosciences Inc. stock remains on buy lists2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com
Caribou Biosciences Soars Over 120%What's Driving The Rally? - Nasdaq
Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study - statnews.com
Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan
What machine learning models say about Caribou Biosciences Inc.July 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
Using Bollinger Bands to evaluate Caribou Biosciences Inc.2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Statistical indicators supporting Caribou Biosciences Inc.’s strengthDay Trade & Precise Buy Zone Tips - newser.com
Published on: 2025-11-03 00:52:40 - newser.com
Caribou Biosciences to Host Webcast Reporting New Clinical Data for Anti-CD19 and Anti-BCMA CAR-T Cell Therapies - Quiver Quantitative
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - The Manila Times
Risk adjusted return profile for Caribou Biosciences Inc. analyzedForecast Cut & Weekly Consistent Profit Watchlists - newser.com
Is Caribou Biosciences Inc. stock a contrarian buyEarnings Beat & High Accuracy Buy Signal Tips - newser.com
Caribou Biosciences Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Intraday pattern recognizer results for Caribou Biosciences Inc.2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
Caribou Biosciences Advances CRISPR-Edited CAR-T Therapy in Lymphoma Study - TipRanks
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):